Clinical trials: Anlotinib
Locally Advanced Non-small Cell Lung Cancer, Efficacy and Safety
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
This is a prospective, randomized, controlled phase II clinical study for evaluating anlotinib combined with concurrent chemoradiotherapy followed by consolidation immunotherapy versus concurrent chemoradiotherapy followed by…
- Trial name
- NCT05481775
- Testing
- Anlotinib, Chemotherapy, Radiotherapy
- Where
- China
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.
- Trial name
- NCT02461407
- Testing
- Anlotinib
- Where
- 38 sites in China
- Volunteers
- 378 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer, Immunotherapy
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric cancer with ECOG 2 as first-line regimen.
- Conditions
- Gastric Cancer, Immunotherapy, Anlotinib, Toripalimab
- Trial name
- NCT04278222
- Testing
- Anlotinib Plus Toripalimab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Changzheng Hospital
Triple Negative Breast Cancer
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
This is an open-label, single-arm, multicenter phase I/II study to evaluate the safety and efficacy of sac-TMT plus anlotinib in previously treated mTNBC. The study is expected to enroll up to 59 eligible patients.
- Trial name
- NCT07139470
- Testing
- Sacituzumab Tirumotecan + anlotinib
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
Advanced esophageal squamous cell carcinoma patients who have failed first-line PD-1 inhibitor combined with chemotherapy lack a standard treatment option.
- Trial name
- NCT05990231
- Testing
- Cadonilimab combined Anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-Small Cell Lung Cancer
Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of anlotinib in…
- Trial name
- NCT03998085
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
Advanced Cholangiocarcinoma
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT03996408
- Testing
- Anlotinib, TQB2450
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Small-Cell Lung Cancer
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03728374
- Testing
- Anlotinib
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Carcinoma, Gastrointestinal Diseases
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma.
- Conditions
- Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer
- Trial name
- EXPLORING (NCT05494060)
- Testing
- Anlotinib hydrochloride capsule, Penpulimab Injection, XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-Clear Cell Renal Cell Carcinoma
Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma
This study will compare benmelstobart plus anlotinib with sunitinib as the first treatment for adults with advanced non-clear cell renal cell carcinoma, a type of kidney cancer.
- Trial name
- NCT07881900
- Testing
- Benmelstobart, Anlotinib, Sunitinib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sun Yat-sen University
Malignant Glioma
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after radiotherapy.
- Trial name
- NCT04197492
- Testing
- Hypofractionated Stereotactic Radiotherapy, Anlotinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Huashan Hospital
Thyroid Neoplasms
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
This multicenter registry tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion/mutation, isolated TERT mutation, triple-negative BRAF/RET/TERT, or ICI ± TKI) can render locally…
- Trial name
- NCT07010393
- Testing
- Dabrafenib, Trametinib, Selpercatinib
- Where
- China
- Volunteers
- 335 people
- Sponsor
- Fujian Medical University
Patients With Digestive System Tumors Resistant to PD-1 Inhibitors
Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors
This clinical study focused on patients with digestive system tumors resistant to PD-1 inhibitors, and explored the reversal resistance of epigenetic drugs (decitabine) and TKI drugs (anlotinib) in this part of patients.
- Trial name
- NCT04611711
- Testing
- decitabine＋ TQB2450 injection, decitabine＋ TQB2450 injection＋Anlotinib
- Volunteers
- 60 people
- Sponsor
- Peking University
HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
This study aims to evaluate the efficacy and safety of adding the anti-angiogenic agent anlotinib to the combination of the CDK2/4/6 inhibitor Culmerciclib and endocrine therapy in patients with HR+/HER2- breast cancer and brain…
- Trial name
- NCT07745257
- Testing
- Culmerciclib, Anlotinib, Endocrine Therapy
- Where
- 9 sites in China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
This study aimed to evaluate the efficacy and safety of third-generation EGFR-TKI plus anlotinib as maintenance after chemotherapy plus immunotherapy in advanced NSCLC with small cell transformation after EGFR-TKI resistance.
- Trial name
- NCT06634667
- Testing
- third-generation EGFR-TKI combined with anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital
Medullary Thyroid Cancer (MTC)
A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
This trial is a prospective, observational Phase II clinical study. For patients with locally advanced and/or metastatic medullary thyroid carcinoma with RET gene mutations who require systemic treatment, they are randomly…
- Trial name
- NCT07048964
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SCLC, Extensive Stage, Lung Cancer
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
To evaluates the effectiveness and safety of Toripalimab combined with Anlotinib and chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Toripalimab combined with Anlotinib.
- Conditions
- SCLC, Extensive Stage, Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04731909
- Testing
- Toripalimab, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Military Medical University
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy.
- Trial name
- NCT04385550
- Testing
- Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection
- Where
- 45 sites in China
- Volunteers
- 528 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colon Cancer, Immunotherapy
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
- Trial name
- NCT06573424
- Testing
- Tislelizumab+anlotinib, anlotinib
- Where
- China
- Volunteers
- 124 people
- Sponsor
- fan li
HER2-Negative Breast Cancer
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
Angiogenesis inhibition represents a significant therapeutic target in breast cancer; however, despite its theoretical feasibility, progress in advanced breast cancer has been slow.
- Trial name
- NCT07396454
- Testing
- Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University